News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelliCell BioSciences (SVFC) Announces the Licensing of its Proprietary Patent, Pending Stromal Vascular Fraction Manufacturing Technology



1/10/2012 7:21:52 AM

NEW YORK--(BUSINESS WIRE)--Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES